Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
- PMID: 20525678
- DOI: 10.1136/bmj.c2519
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
Abstract
Objectives: To determine the risk of stroke associated with oral and transdermal routes of administration of hormone replacement therapy.
Design: Population based nested case-control study. Setting About 400 general practices in the United Kingdom contributing to the General Practice Research Database. Participants Cohort of all women in the database aged 50-79 years between 1 January 1987 and 31 October 2006 who were members of a practice that fulfilled predefined quality criteria and without a diagnosis of stroke before cohort entry. For each case of stroke occurring during follow-up, up to four controls were selected from among the cohort members in the risk sets defined by the case. Exposure to hormone replacement therapy (HRT) was categorised into oestrogens only, oestrogens plus progestogen, progestogen only, and tibolone. Oestrogens were further subdivided according to the route of administration (oral v transdermal) and dose (high v low). Main outcome measures Rate ratio of stroke associated with current use of oral and transdermal HRT compared with no use. Current use was considered as a prescription whose duration included the index date.
Results: There were 15,710 cases of stroke matched to 59 958 controls. The rate of stroke in the cohort was 2.85 per 1000 per year. The adjusted rate ratio of stroke associated with current use of transdermal HRT was 0.95 (95% CI 0.75 to 1.20) relative to no use. The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)). Current users of oral HRT had a higher rate of stroke than non-users (rate ratio 1.28 (1.15 to 1.42)) with both low dose and high dose.
Conclusions: The use of transdermal HRT containing low doses of oestrogen does not seem to increase the risk of stroke. The presence of residual confounding, however, cannot be entirely excluded in the interpretation of this finding.
Similar articles
-
Hormone replacement therapy use and the risk of stroke.Maturitas. 2008 Dec 20;61(4):305-9. doi: 10.1016/j.maturitas.2008.09.020. Epub 2008 Nov 8. Maturitas. 2008. PMID: 18996656
-
Hormone replacement therapy use and variations in the risk of breast cancer.BJOG. 2008 Jan;115(2):169-75; discussion 175. doi: 10.1111/j.1471-0528.2007.01520.x. BJOG. 2008. PMID: 18081598
-
Transdermal hormone therapy and the risk of stroke and venous thrombosis.Climacteric. 2010 Oct;13(5):429-32. doi: 10.3109/13697137.2010.507111. Climacteric. 2010. PMID: 20670199
-
Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.Acta Endocrinol (Copenh). 1991;125 Suppl 1:13-26. Acta Endocrinol (Copenh). 1991. PMID: 1801500 Review.
-
[Hormone replacement therapy for internal risk patients].Gynakol Geburtshilfliche Rundsch. 2006;46(4):174-90. doi: 10.1159/000095726. Gynakol Geburtshilfliche Rundsch. 2006. PMID: 17068402 Review. German.
Cited by
-
Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke.Horm Behav. 2013 Feb;63(2):238-53. doi: 10.1016/j.yhbeh.2012.04.007. Epub 2012 Apr 24. Horm Behav. 2013. PMID: 22561337 Free PMC article. Review.
-
Cardiovascular health in transgender people.Rev Endocr Metab Disord. 2018 Sep;19(3):243-251. doi: 10.1007/s11154-018-9454-3. Rev Endocr Metab Disord. 2018. PMID: 30073551 Review.
-
Prescribing menopausal hormone therapy: an evidence-based approach.Int J Womens Health. 2014 Jan 11;6:47-57. doi: 10.2147/IJWH.S38342. eCollection 2014. Int J Womens Health. 2014. PMID: 24474847 Free PMC article. Review.
-
Women and stroke: disparities in clinical presentation, severity, and short- and long-term outcomes.Front Neurol. 2023 May 15;14:1147858. doi: 10.3389/fneur.2023.1147858. eCollection 2023. Front Neurol. 2023. PMID: 37255725 Free PMC article.
-
The 2012 hormone therapy position statement of: The North American Menopause Society.Menopause. 2012 Mar;19(3):257-71. doi: 10.1097/gme.0b013e31824b970a. Menopause. 2012. PMID: 22367731 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical